Seres Therapeutics Past Earnings Performance
Past criteria checks 0/6
Seres Therapeutics's earnings have been declining at an average annual rate of -17.7%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 26.1% per year.
Key information
-17.7%
Earnings growth rate
4.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 26.1% |
| Return on equity | n/a |
| Net Margin | -65.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Seres Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 127 | -83 | 81 | 0 |
| 31 Dec 23 | 126 | -114 | 88 | 0 |
| 30 Sep 23 | 127 | -141 | 93 | 0 |
| 30 Jun 23 | 130 | -153 | 91 | 0 |
| 31 Mar 23 | 5 | -265 | 84 | 0 |
| 31 Dec 22 | 7 | -250 | 80 | 0 |
| 30 Sep 22 | 13 | -231 | 78 | 0 |
| 30 Jun 22 | 137 | -103 | 79 | 0 |
| 31 Mar 22 | 141 | -87 | 76 | 0 |
| 31 Dec 21 | 145 | -66 | 69 | 0 |
| 30 Sep 21 | 155 | -34 | 59 | 0 |
| 30 Jun 21 | 30 | -132 | 47 | 0 |
| 31 Mar 21 | 31 | -105 | 36 | 0 |
| 31 Dec 20 | 33 | -89 | 31 | 0 |
| 30 Sep 20 | 23 | -90 | 26 | 0 |
| 30 Jun 20 | 29 | -76 | 24 | 0 |
| 31 Mar 20 | 35 | -66 | 23 | 0 |
| 31 Dec 19 | 35 | -70 | 25 | 0 |
| 30 Sep 19 | 38 | -73 | 26 | 0 |
| 30 Jun 19 | 40 | -78 | 28 | 0 |
| 31 Mar 19 | 32 | -95 | 31 | 0 |
| 31 Dec 18 | 28 | -99 | 33 | 0 |
| 30 Sep 18 | 21 | -107 | 34 | 0 |
| 30 Jun 18 | 35 | -92 | 34 | 0 |
| 31 Mar 18 | 33 | -92 | 34 | 0 |
| 31 Dec 17 | 32 | -89 | 34 | 0 |
| 30 Sep 17 | 32 | -86 | 34 | 0 |
| 30 Jun 17 | 22 | -97 | 34 | 0 |
| 31 Mar 17 | 22 | -97 | 34 | 0 |
| 31 Dec 16 | 22 | -92 | 33 | 0 |
| 30 Sep 16 | 19 | -86 | 30 | 0 |
| 30 Jun 16 | 6 | -82 | 27 | 0 |
| 31 Mar 16 | 3 | -67 | 21 | 0 |
| 31 Dec 15 | 0 | -55 | 17 | 0 |
| 30 Sep 15 | 0 | -44 | 13 | 5 |
| 30 Jun 15 | 0 | -34 | 9 | 8 |
| 31 Mar 15 | 0 | -24 | 6 | 10 |
| 31 Dec 14 | 0 | -18 | 4 | 0 |
| 30 Sep 14 | 0 | -12 | 3 | 7 |
Quality Earnings: 1S9 is currently unprofitable.
Growing Profit Margin: 1S9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1S9 is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare 1S9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1S9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.8%).
Return on Equity
High ROE: 1S9's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.